In 4,554 matched patients with type 2 diabetes and CKD, GLP-1/GIP drugs were tied to a 29% lower relative hazard of kidney decline than finerenone over 2.5 years.
Recap by typeshit. Post by @kamleshkhunti on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
A new 'In Discussion With' episode features Sehar Shahid on what makes losing weight difficult. Little else is shared beyond the topic.
An investor angle arguing Lilly's triple agonist could become a bigger growth driver than Zepbound, ahead of the company's quarterly report.
Loading…